Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma.

@article{Li2016PhaseIS,
  title={Phase I study of concurrent selective lymph node late-course accelerated hyperfractionated radiotherapy and S-1 plus cisplatin for locally advanced oesophageal squamous cell carcinoma.},
  author={Miaomiao Li and Chengrui Fu and Wei Zhang and Wei Huang and Zhongtang Wang and Tao Zhou and Haiqun Lin and Baosheng Li},
  journal={The British journal of radiology},
  year={2016},
  volume={89 1060},
  pages={20150476}
}
OBJECTIVE This Phase I study aimed to assess the safety and efficacy of concurrent selective lymph node (SLN) late-course accelerated hyperfractionated (LCAF) intensity-modulated radiotherapy (IMRT) and S-1 plus cisplatin (CDDP) for the locally advanced oesophageal squamous-cell carcinoma (ESCC). METHODS The total dose of SLN LCAF IMRT was 59.6 Gy/34 fractions in 5.4 weeks. The concurrent chemotherapy (CCRT) was administered as follows: CDDP 25 mg m(-2) on Days 1-3 and Days 22-24; S-1 was… CONTINUE READING